All In Biotech

Drug Trial Radar · NCT02405442

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Apr 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

187

Actual

Start

Apr 30, 2015

Primary completion

Nov 30, 2016

Study completion Dec 22, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.

Conditions

  • Crohn's Disease

Interventions

  • AndecaliximabDrug

    Andecaliximab administered via subcutaneous (SC) injection

  • PlaceboDrug

    Placebo to match andecaliximab administered via SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind PhaseTime frame: Week 8
  2. Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind PhaseTime frame: Week 8

Locations

74 sites in 13 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of The Southeast

    Dothan, Alabama

  • Mayo Clinic

    Scottsdale, Arizona

  • Cedars Sinai Medical Center

    Los Angeles, California

  • South Denver Gastroenterology

    Lone Tree, Colorado

  • University of Miami

    Miami, Florida

  • Gastroenterology Group Of Naples

    Naples, Florida

  • Gastroenterology Associates Of Central Georgia, LLC

    Macon, Georgia

  • Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital

    Indianapolis, Indiana

  • Iowa Digestive Disease Center

    Clive, Iowa

  • Cotton-O'Neil Clinical Research Center, Digestive Health

    Topeka, Kansas

  • Delta Research Partners

    Monroe, Louisiana

  • Louisiana Research Center

    Shreveport, Louisiana

  • University of Michigan

    Ann Arbor, Michigan

  • Clinical Research Institute of Michigan, LLC

    Chesterfield, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • AGA Clinical Research Associates, LLC

    Egg Harbor, New Jersey

  • Columbia University Medical Center/ New York Presbyterian

    New York, New York

  • Premier Medical Group Of The Hudson Valley

    Poughkeepsie, New York

  • Mayo Clinic Rochester

    Rochester, New York

  • Asheville Gastroenterology Associates

    Asheville, North Carolina

  • Consultants For Clinical Research

    Cincinnati, Ohio

  • Great Lakes Gastroenterology

    Mentor, Ohio

  • Gastro One

    Germantown, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Clinical Research Institute

    Arlington, Texas

  • Ertan Digestive Disease Center of Excellence, UTH/MH-TMC

    Houston, Texas

  • Gastroenterology Research of San Antonio

    San Antonio, Texas

  • Gastroenterology Associates Of Tidewater

    Chesapeake, Virginia

  • Digestive and Liver Disease Specialists

    Norfolk, Virginia

  • Mcguire Dvamc

    Richmond, Virginia

  • University of Washington Medical Center

    Seattle, Washington

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Footscray Hospital

    Footscray, Victoria, Australia

  • Gastroenterology/Colorectal Medicine & Genetics

    Melbourne, Victoria, Australia

  • Percuro Clinical Research Ltd.

    Victoria, Canada

  • Percuro Clinical Research Ltd.

    Victoria, British Columbia, Canada

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.